DSGN - Design Therapeutics Inc

DSGN - Design Therapeutics Inc

https://www.designtx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Design Therapeutics Appoints Justin Gover to Board of Directors - Compass Pathways ( NASDAQ:CMPS ) , Design Therapeutics ( NASDAQ:DSGN )

Benzinga • 4 days, 19 hours ago • score: 0.29

CARLSBAD, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective ...

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.03

CARLSBAD, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( Nasdaq: DSGN ) , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global ...

Design Therapeutics ( DSGN ) Upgraded to Buy: Here's Why

Zacks Commentary • 6 months ago • score: 0.33

Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Dave ( NASDAQ:DAVE ) , ARKO ( NASDAQ:ARKO )

Benzinga • 8 months, 2 weeks ago

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Sangamo Therapeutics, Inc. SGMO fell sharply in today's pre-market trading as the company announced its collaboration and license agreement with Pfizer on giroctocogene ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.

52W High

$7.77

52W Low

$2.60

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.62

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.84

EV/Revenue (<3 favorable)

11004.35

P/S (TTM) (<3 favorable)

22642.01

P/B (<3 favorable)

1.72

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

35.98%

Institutions (25–75% balanced)

63.03%

Shares Outstanding

56,948,000

Float

23,335,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

33,000

Gross Profit (TTM)

-44,531,000

EPS (TTM)

-1.12

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.27%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.5484

Previous

0.4924

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025